|
| Status |
Public on Aug 21, 2022 |
| Title |
RNA data of MKN45 tumours treated with ERY974 and/or capecitabine in huNOG mice |
| Organisms |
Homo sapiens; Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
We found that ERY974 shows only moderate antitumor efficacy in MKN45 non-inflamed tumor in huNOG mice. We also observed that ERY974 + capecitabine increases antitumour efficacy in non-inflamed MKN45 tumours.
To identify a mechanism of combination effect, we compared RNA expression of MKN45 tumors treated with ERY974, capecitabine, or combination.
|
| |
|
| Overall design |
Comparative gene expression profiling analysis of RNA-seq data for tumors treated with ERY974, capecitabine, or combination in huNOG model.
|
| |
|
| Contributor(s) |
Sano Y, Nishito Y, Azuma Y, Kinoshita Y, Tsunenari T, Ishiguro T |
| Citation(s) |
36071036 |
| Submission date |
Aug 16, 2022 |
| Last update date |
Nov 21, 2022 |
| Contact name |
YUJI SANO |
| E-mail(s) |
sanoyuj@chugai-pharm.co.jp
|
| Phone |
+810467476241
|
| Organization name |
Chugai Pharmaceutical Co., Ltd
|
| Street address |
200
|
| City |
Kajiwara |
| State/province |
Kamakura |
| ZIP/Postal code |
247-8530 |
| Country |
Japan |
| |
|
| Platforms (2) |
| GPL22245 |
Illumina HiSeq 2500 (Homo sapiens; Mus musculus) |
| GPL25526 |
Illumina NovaSeq 6000 (Homo sapiens; Mus musculus) |
|
| Samples (24)
|
|
| Relations |
| BioProject |
PRJNA870059 |
Less...
More...